glp 1 ckd Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations | Diabetes Therapy Potential kidney-protective and other effects
Description
doi: 10.1210/endo-103-2-610
The treatment goal for this phase was weight maintenance, not weight loss
Drugs engineered to bind albumin therefore benefit from prolonged systemic exposure
Weight Management Support May help support steady progress toward long-term weight management goals for appropriate patients
